Alembic Pharmaceuticals Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Alembic Pharmaceuticals Ltd filed with BSE on 21 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Alembic Pharmaceuticals reported Q4 FY26 revenue of Rs 1,838 crores, up 4% year-on-year, with EBITDA before R&D at Rs 455 crores, up about 8%. For the full year, revenue grew 10% and reported profit after tax grew 16% to Rs 675 crores. Management discussed a drag from the newly launched U.S. branded product Pivya and outlined a directional outlook for FY27 including low double-digit consolidated revenue growth and R&D spend of Rs 750-800 crores.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Revenue from operations: INR1,838 crores (Q4 FY26)
p. 7
“For the quarter, revenue from operations stood at INR1,838 crores, up by 4% year-on-year.”
G. Krishnan, page 7 of the filed PDF · View the filing
EBITDA before R&D: INR455 crores (Q4 FY26)
p. 7
“On the operating front, EBITDA before R&D stood at INR455 crores, up by about 8% year-on-year with core margins at almost at 25% compared to 24% in the previous year, same quarter.”
G. Krishnan, page 7 of the filed PDF · View the filing
Gross margin: 71% (Q4 FY26)
p. 7
“This reflects better business mix with slightly better gross margins at 71%, but staying in the previously mentioned range of about 70% to 75%.”
G. Krishnan, page 7 of the filed PDF · View the filing
R&D spending: INR209 crores (Q4 FY26)
p. 7
“R&D spending for the quarter was at INR209 crores compared with INR151 crores in the same quarter last year, representing”
G. Krishnan, page 7 of the filed PDF · View the filing
R&D as % of revenue: 11% (Q4 FY26)
p. 8
“11% of revenue versus 9% last year.”
G. Krishnan, page 8 of the filed PDF · View the filing
Reported profit after tax: INR203 crores (Q4 FY26)
p. 8
“At the profit level, the reported profit after tax for the quarter stood at INR203 crores.”
G. Krishnan, page 8 of the filed PDF · View the filing
Gross debt: INR1,361 crores (Q4 FY26)
p. 8
“Gross debt was at INR1,361 crores broadly in line with the December levels.”
G. Krishnan, page 8 of the filed PDF · View the filing
Revenue growth: 10% (FY26)
p. 8
“For the full year, revenue grew by about 10% year-on-year, supported by growth across businesses, while absorbing a higher level of investment in R&D and strategic growth initiatives.”
G. Krishnan, page 8 of the filed PDF · View the filing
EBITDA before R&D and exceptional items: INR1,846 crores (FY26)
p. 8
“For FY '26, EBITDA before R&D and exceptional items stood at INR1,846 crores, representing 25% of revenue and a 20% yearon-year growth.”
G. Krishnan, page 8 of the filed PDF · View the filing
EBITDA after R&D: 17% of revenue (FY26)
p. 8
“EBITDA after R&D was at 17% of revenue.”
G. Krishnan, page 8 of the filed PDF · View the filing
Reported profit after tax growth: 16% to INR675 crores (FY26)
p. 8
“Reported profit after tax grew at 16% to INR675 crores.”
G. Krishnan, page 8 of the filed PDF · View the filing
India business growth: 4% (Q4 FY26)
p. 4
“The business delivered 4% yearon-year growth.”
Pranav Amin, page 4 of the filed PDF · View the filing
India business growth: 5% (FY26)
p. 4
“For the full year, India business delivered a growth of 5%.”
Pranav Amin, page 4 of the filed PDF · View the filing
Ex-U.S. markets growth: 20% (FY26)
p. 5
“The ex U.S. markets also continued doing well and grew 20% for the year, whilst the quarter was muted, but the full year grew 20%.”
Pranav Amin, page 5 of the filed PDF · View the filing
New U.S. launches: 6 (Q4 FY26)
p. 5
“During the quarter, we had 6 new launches in the U.S. further ANDA filings and approvals and progress on partnership-led opportunities.”
Pranav Amin, page 5 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Consolidated top line growth — low double-digit range · FY27
stated conditionally by Pranav Amin
p. 6
“This will translate into an overall top line consolidated growth to be in the low double-digit range .”
Pranav Amin, page 6 of the filed PDF · View the filing
R&D investment — INR750 crores to INR800 crores · FY27
stated firmly by Pranav Amin
p. 6
“R&D investments are likely to be around INR750 crores to INR800 crores as we calibrate our portfolio and structurally move”
Pranav Amin, page 6 of the filed PDF · View the filing
International generic business growth — low to mid-teen range · FY27
stated conditionally by Pranav Amin
p. 6
“The international generic business are also likely to grow at a decent amount by low to mid-teen range and the API business to grow in the high single or low double-digit growth.”
Pranav Amin, page 6 of the filed PDF · View the filing
India business growth — closer to market growth · FY27
stated as an aspiration by Pranav Amin
p. 6
“We expect the India business to improve and growth momentum and hope to be closer to market growth with a renewed approach to strengthen focused brands.”
Pranav Amin, page 6 of the filed PDF · View the filing
Capital expenditure — INR300 crores to INR350 crores · FY27
stated firmly by G. Krishnan
p. 9
“We expect capital expenditure for the year to be in the range of INR300 crores to INR350 crores, primarily towards capacity, debottlenecking and replacement capex.”
G. Krishnan, page 9 of the filed PDF · View the filing
U.S. business growth — 10% to 15% · FY27
stated as an aspiration by Pranav Amin
p. 14
“I expect the U.S. business to grow between 10% to 15% at least.”
Pranav Amin, page 14 of the filed PDF · View the filing
ROW business growth — 15-plus percent · FY27
stated as an aspiration by Pranav Amin
p. 14
“The ROW will continue the growth at 15-plus percent.”
Pranav Amin, page 14 of the filed PDF · View the filing
API business growth — closer to 10% · FY27
stated as an aspiration by Pranav Amin
p. 14
“API will be closer to the 10% growth.”
Pranav Amin, page 14 of the filed PDF · View the filing
EBITDA margin — 20% kind of EBITDA margins · 2, 3 year period
stated as an aspiration by Pranav Amin
p. 14
“As I mentioned, at some point, we would go back up to the 20% kind of EBITDA margins over a 2, 3 year period.”
Pranav Amin, page 14 of the filed PDF · View the filing
R&D spend as % of revenue — 8% to 9% · FY27
stated firmly by Pranav Amin
p. 13
“We're measuring it by opportunity-to-opportunity. The only way we can grow is that we do have products in the market. And hence, we will not go up to the 15% levels, but it's 8% to 9% of revenues where we'll be at.”
Pranav Amin, page 13 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said both facilities are running at much higher occupancy, with some lines like ophthalmic near full capacity, and that unabsorbed cost is not a major issue.
Answered by Pranav Amin
Asked by Jahnvi Mishra: How much cost do the underutilized F2 and F3 facilities add to the P&L, and when will they start covering their own cost?
p. 9
“Both F2 and F3 are working at a much higher occupancy level than they used to.”
Pranav Amin, page 9 of the filed PDF · View the filing
Management said contribution has already started and will continue into FY27.
Answered by Pranav Amin
Asked by Jahnvi Mishra: Will contract manufacturing deals for F2/F3 generate meaningful revenue in FY27?
p. 10
“No, it's already started. Some of the licensing and some of the contract manufacturing is in progress. So we'll see part contribution from that in FY '27 itself.”
Pranav Amin, page 10 of the filed PDF · View the filing
Management quantified about 100-150 basis points of impact from the branded U.S. business and expects core business margins to offset it in FY27.
Answered by G. Krishnan
Asked by Rahul Jeewani: What was the margin impact from the Pivya launch this quarter and going forward?
p. 11
“So, from a modeling point of view, I would take about 100 to 150 basis points of impact coming from Pivya, from the branded business in U.S.”
G. Krishnan, page 11 of the filed PDF · View the filing
Management said each R&D project is assessed on an IRR basis and that spend as a percentage of revenue would come back down.
Answered by Pranav Amin
Asked by Rahul Jeewani: How is R&D productivity measured given rising spend?
p. 12
“we generally have an IRR for each of our R&D projects. That's what we base our calculations on and what makes sense.”
Pranav Amin, page 12 of the filed PDF · View the filing
Management said they expect margin improvement this year as the Pivya drag fades and core business grows, but declined to give a specific number.
Answered by Pranav Amin
Asked by Rahul Jeewani: Can margins improve over FY26 levels given Pivya drag and improving F2/F3 utilization?
p. 14
“We will see -- definitely see an improvement in the margins this year.”
Pranav Amin, page 14 of the filed PDF · View the filing
Management confirmed the 10-15% figure is in INR terms while reiterating it is not formal guidance.
Answered by Pranav Amin
Asked by Tushar Manudhane: Is the U.S. guidance of 10-15% in INR terms, implying lower constant currency growth?
p. 14
“I'm saying, yes, in terms of INR terms, I mentioned 10% to 15%.”
Pranav Amin, page 14 of the filed PDF · View the filing
Management said the peptide capex is largely complete and was part of an existing API facility rather than a dedicated peptide investment.
Answered by Pranav Amin
Asked by Tushar Manudhane: What investment has been made in peptides in terms of R&D and capex?
p. 15
“So capex is all done. We've already completed the capex of the peptides.”
Pranav Amin, page 15 of the filed PDF · View the filing
Management said the portfolio includes 5-6 products, two of which are already filed.
Answered by Pranav Amin
Asked by Tushar Manudhane: How many peptide filings are expected over the next 12 months?
p. 15
“We've got a couple. The portfolio is about 5 to 6 that we had. Two of them are filed already and the rest are going on.”
Pranav Amin, page 15 of the filed PDF · View the filing
Management said input cost increases have not yet been passed on and are not materially impacting margins due to higher inventory levels.
Answered by Pranav Amin
Asked by Tushar Manudhane: Have API prices moved up given rising solvent costs linked to crude derivatives?
p. 16
“Have we passed it on? No, it's still not a materially big issue for us.”
Pranav Amin, page 16 of the filed PDF · View the filing
Management said it is too early to share metrics but noted a good initial trend and feedback.
Answered by Pranav Amin
Asked by Tushar Manudhane: Any early color on the branded business post-launch, such as prescription trends?
p. 16
“So we're seeing a good trend. We're seeing good feedback.”
Pranav Amin, page 16 of the filed PDF · View the filing
Management said capex is largely complete and future investment will focus on in-licensing for the branded business and continued, measured R&D spend.
Answered by Pranav Amin
Asked by Tushar Manudhane: Where will capital allocation go in FY27/28 beyond peptides and the branded business?
p. 17
“So on the branded side, we will in-license few more products.”
Pranav Amin, page 17 of the filed PDF · View the filing
Risks flagged
Pricing pressure, competitive intensity, regulatory expectations and supply chain volatility affecting performance
p. 3
“The external environment continues to remain dynamic across the markets, pricing pressure, competitive intensity, regulatory expectation and supply chain volatility, continue to shape the performance.”
Pranav Amin, page 3 of the filed PDF · View the filing
Pricing pressure headwind in the API business
p. 5
“The API business delivered a modest growth in Q4, driven primarily by volumes, while pricing remained a headwind.”
Pranav Amin, page 5 of the filed PDF · View the filing
Short-term profitability impact from the U.S. branded business investment
p. 6
“While there may be a short-term impact on profitability, which should get offset from improved operating leverage in the core business.”
Pranav Amin, page 6 of the filed PDF · View the filing
Muted quarterly ex-U.S. performance due to higher base and one-off variances
p. 5
“The quarterly performance of ex U.S. is mainly muted due to a higher base and one-off variances.”
Pranav Amin, page 5 of the filed PDF · View the filing
Rising solvent input costs linked to crude derivatives
p. 16
“Secondly, in terms of -- are we seeing increase in some solvents? Yes, we're seeing it.”
Pranav Amin, page 16 of the filed PDF · View the filing
Drag on margins from Alembic Therapeutics branded business launch
p. 11
“There was a drag on the business because of that. The product just got launched in February.”
Pranav Amin, page 11 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.